Inventiva SA
PAR:IVA

Watchlist Manager
Inventiva SA Logo
Inventiva SA
PAR:IVA
Watchlist
Price: 2.76 EUR -0.36%
Market Cap: 264m EUR

EV/EBIT
Enterprise Value to EBIT

-3
Current
-3.3
Median
3.7
Industry
Higher than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
-3
=
Enterprise Value
300.7m EUR
/
EBIT
-100.1m EUR
Market Cap EV/EBIT
FR
Inventiva SA
PAR:IVA
264m EUR -3
FR
Pharnext SCA
OTC:PNEXF
6T USD -208 527.2
US
Abbvie Inc
NYSE:ABBV
374.2B USD 26
US
Amgen Inc
NASDAQ:AMGN
169.1B USD 29.4
US
Gilead Sciences Inc
NASDAQ:GILD
131.9B USD 13.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
131.1B USD 28.1
US
Epizyme Inc
F:EPE
94.1B EUR -521.3
AU
CSL Ltd
ASX:CSL
123.3B AUD 21.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
72.6B USD 12.1
US
Seagen Inc
F:SGT
39.3B EUR -55.3
NL
argenx SE
XBRU:ARGX
34B EUR -2 413.4
EBIT Growth EV/EBIT to Growth
FR
Inventiva SA
PAR:IVA
Average EV/EBIT: 21.8
Negative Multiple: -3
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -208 527.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
26
29%
0.9
US
Amgen Inc
NASDAQ:AMGN
29.4
31%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
13.6
10%
1.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
28.1
15%
1.9
US
E
Epizyme Inc
F:EPE
Negative Multiple: -521.3 N/A N/A
AU
CSL Ltd
ASX:CSL
21.8
14%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.1
17%
0.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -55.3 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -2 413.4 N/A N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
-2.6
2-Years Forward
EV/EBIT
-2.9
3-Years Forward
EV/EBIT
-2.9